menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
ReachMD Faculty

Public Profile

Luis Paz-Ares, MD, PhD
Luis Paz-Ares, MD, PhD
  • Head Oncologist
  • Hospital Universitario 12 de Octubre
  • Madrid, Spain
Luis Paz-Ares is currently Chair of the Medical Oncology Department at the Hospital Doce de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center), all in Madrid, Spain. He graduated with a degree in Medicine from the Universidad Autonoma de Madrid, in 1986, and completed a PhD in 1993 at the same university. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, Glasgow, Scotland (1993–1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995. Luis Paz-Ares also completed a Master’s degree in Clinical Unit Management at the UNED-Fundación Universidad Empresa (2002–2003). Prior to his current position, he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014), Head of the Pharmacology Unit and responsible for early clinical studies of thoracic and genitourinary tumours at the University Hospital "12 de Octubre" in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000). Luis Paz-Ares’s research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 200 articles in peer review journals including New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and many others. He has served as a member of several committees, including ASCO and ESMO meeting Scientific Committees, European Organisation for Research and Treatment of Cancer Protocol Review Committee and Audit Committee, the Spanish Agency of Medicines and Medical Devices and the European Medicines Agency.
Schedule18 Apr 2024